Market Access JPM 2026: What it revealed about biotech’s new reality JPM 2026 signalled genuine recovery – but not the kind the industry has historically celebrated.
R&D Strategies for creating an ecosystem to support early-stage ... Learn how to foster growth for early-stage biotech companies through innovative ecosystem strategies and valuable CDMO collaborations
Market Access How can biotech survive its funding winter? Some may argue that VCs and public markets have turned against biotech, but the reality is they have become much more sceptical.
Market Access From roasts to billions: Navigating the biopharma investment... At BIO-Europe, the session “From Roasts to Billions: Biopharma Investment Landscape” brought together leading voices from investment banking & VC.
R&D The glimmer of opportunity behind the storm: Ali Pashazadeh ... Former surgeon and investment banker Ali Pashazadeh, CEO of Treehill, discusses the current ‘perfect storm’ in biotech.
Market Access Biotech ≠ tech: Why venture capital needs a new playbook for... Silicon Valley investors have been conditioned by two decades of software: launch quickly, capture users faster, and hit the magic $1 million ARR mark within about three years,1
News UK says it has hit target on commercial trial set-up times The UK has made progress in its efforts to slash set-up times for clinical trials, one of the factors blamed for a decline in industry-backed studies.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
